Simparica TRIO Chews for Dogs 88.1-132 lbs (40.1-60 kg)

Description

Simparica TRIO Chews for Dogs 88.1-132 lbs (40.1-60 kg) is a triple-active oral chewable manufactured by Zoetis, delivering 72 mg sarolaner, 1.44 mg moxidectin, and 300 mg pyrantel per tablet, formulated for giant and large working breeds including Great Danes, Saint Bernards, Mastiffs, and similarly sized dogs at the upper end of the canine weight spectrum. Each monthly dose addresses fleas, six tick species, heartworm larvae, tapeworm prevention, and intestinal nematodes including roundworms and hookworms.

Dogs exceeding 132 lbs (60 kg) fall outside all single-tablet labeled variants and require an appropriate combination of tablets to reach the minimum therapeutic dose; consult a veterinarian before administering to dogs above this threshold.

Recommended for

Dogs weighing 88.1 to 132 lbs (40.1 to 60 kg) from 8 weeks of age and older.

Indication/Coverage

For dogs suffering from, or at risk of, mixed parasitic infections, Simparica TRIO delivers coverage across the following conditions:

• Heartworm prevention: Prevention of heartworm disease caused by Dirofilaria immitis through elimination of susceptible L3/L4 larval stages.
• Flea treatment and prevention: Elimination of adult fleas (Ctenocephalides felis); prevents re-establishment of flea infestations within each monthly dosing cycle.
• Tapeworm prevention: Prevents Dipylidium caninum infections as a direct result of eliminating Ctenocephalides felis vector fleas on the treated dog.
• Tick treatment and control: Treatment and control of infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (Asian longhorned tick).
• Lyme disease prevention: Prevents Borrelia burgdorferi infection as a direct result of eliminating Ixodes scapularis vector ticks on the treated dog.
• Roundworm treatment and control: Treatment and control of Toxocara canis (immature adults and adults) and Toxascaris leonina (adults).
• Hookworm treatment and control: Treatment and control of Ancylostoma caninum (L4 larvae, immature adults, and adults) and Uncinaria stenocephala (adults).

Key Benefits

The following characteristics are grounded in the Zoetis product label and supporting clinical data, applicable to dogs in the 88.1 to 132 lb weight band:

• Purpose-built for giant breeds: The 72 mg sarolaner dose in this variant is calibrated to deliver the minimum therapeutic concentration of 1.2 mg/kg across the full 88.1 to 132 lb range, ensuring dogs at the lower and upper ends of this band receive equivalent pharmacological coverage.
• Broad parasite scope in one dose: A single monthly tablet addresses fleas, six tick species, heartworm larval stages, intestinal roundworms, hookworms across three life stages, and prevents tapeworm and Lyme disease transmission, without requiring supplementary products.
• Flea kill begins at 4 hours: Laboratory efficacy data confirm that Simparica TRIO begins eliminating adult fleas within 4 hours of oral administration and achieves 100% kill at 8 hours, limiting flea feeding and egg deposition on the first day of each dosing cycle.
• Tick protection across all six species: Against scapularis, a reduction of at least 94.2% in live tick burden within 24 hours of re-infestation is sustained across the 28-day interval; against A. americanum, at least 99.4% efficacy is reached within 72 hours, covering the full range of tick species encountered by large outdoor dogs.
• Hookworm clearance across life stages: Pyrantel pamoate acts as a depolarizing neuromuscular blocker in susceptible nematodes, documented to clear caninum at L4, immature adult, and adult stages and T. canis at immature adult and adult stages within a single monthly administration.
• Lyme disease prevention for large working dogs: Two controlled laboratory studies confirmed prevention of Borrelia burgdorferi transmission following scapularis infestation at 28 days post-treatment, a clinically significant outcome for giant breeds used in field, tracking, or patrol work in tick-endemic regions.
• Water exposure does not reduce efficacy: Because all three active compounds act systemically following oral absorption, bathing, swimming, or rain exposure between doses has no impact on parasite coverage, a practical advantage for large water-retrieving or working breeds.
• Oral format suited to dense-coated giant breeds: Applying a topical spot-on to the skin surface of heavily coated giant breeds is prone to coat absorption rather than skin penetration; the chewable format bypasses this application challenge entirely by delivering active compounds via the gastrointestinal tract.

Caution

Hazards to Humans

Keep out of reach of children. Simparica TRIO is formulated exclusively for oral administration to dogs; human ingestion requires immediate medical attention. Wash hands after handling tablets and before any food contact. Avoid transferring tablet fragments to the eyes or broken skin.

Hazards to Domestic Animals

Simparica TRIO is for oral use in dogs only; do not administer to cats or other species. This variant is not appropriate for dogs below 88.1 lbs (40.1 kg) or younger than 8 weeks of age. Sarolaner is an isoxazoline-class compound associated with neurologic adverse reactions including tremors, ataxia, and seizures; use with caution in dogs with a history of seizures or neurological disorders. The safety of Simparica TRIO has not been established in breeding, pregnant, or lactating dogs; veterinary consultation is required before use in these animals. Dogs that are debilitated or receiving concurrent medications should be evaluated by a veterinarian prior to administration.

Possible Side Effects

Monitor your dog attentively after each Simparica TRIO administration, with particular vigilance during the first 48 hours following the initial dose.

The adverse reactions below were documented across three field safety studies conducted by Zoetis; primary incidence figures are derived from 272 dogs receiving monthly treatment for up to 11 cycles:

• Vomiting: Reported in 14.3% of treated dogs in the principal study; the most consistently recorded reaction across all three field studies and noted in both the flea and roundworm treatment study populations.
• Diarrhea: Observed in 13.2% of treated dogs, with or without blood in post-approval reporting; rates were elevated in dogs with active roundworm infections at the time of first dosing.
• Lethargy: Recorded in 8.5% of treated dogs; characteristically transient and self-resolving across the study population.
• Anorexia: Reported in 5.1% of treated dogs, at a frequency consistent with the active control group.
• Polyuria: Observed in 3.7% of treated dogs within the primary field study.
• Hyperactivity: Reported in 2.2% of Simparica TRIO-treated dogs versus 0.7% in the active control group.
• Seizures: Confirmed in one dog in a controlled laboratory study 16 days post-administration; post-approval FDA/CVM data categorize seizure as a known class-level risk for isoxazoline compounds.
• Muscle tremors and ataxia: Present in post-approval adverse drug experience reports filed with FDA/CVM; no reliable frequency estimate can be derived from spontaneous post-market submissions alone.

If any reaction persists, worsens, or is of concern following dosing, discontinue administration and contact a veterinarian.